Literature DB >> 12715370

[Role of cytokines in the development of immunologic and homeostatic disorders in advanced dysplasia and carcinoma of the uterine cervix].

T E Belokrinitskaia1, Iu A Vitkovskiĭ, Iu N Ponomareva.   

Abstract

Immunological status, levels of pro-inflammatory cytokines of non-specific resistance and tumor expression factor have been studied in patients with cervical dysplasia or cancer versus stage. Slight and moderate dysplasia involved virtually no changes in interleukin-8 (Il-8) and tumor necrotic factor TNF-alpha concentrations whereas those of Il-1 alpha and Il-1 beta were 5 times as high. Monocyte-dependent expression of tissue factor was similar to that in healthy women. In cases of advanced dysplasia and cervical carcinoma, monocyte-dependent expression of tissue factor and production of Il-1 alpha, Il-1 beta, Il-8 and TNF-alpha were significantly enhanced. Patients with cervical carcinoma stage II and III revealed signs of depression of the cellular component of immunity as well as non-specific resistance. Hence, increased concentrations of cytokines induce monocyte-dependent expression of tissue factor in advanced dysplasia and cervical carcinoma by triggering-on of hypercoaggulation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12715370

Source DB:  PubMed          Journal:  Vopr Onkol        ISSN: 0507-3758


  2 in total

1.  Dual infection with Helicobacter bilis and Helicobacter hepaticus in p-glycoprotein-deficient mdr1a-/- mice results in colitis that progresses to dysplasia.

Authors:  Lillian Maggio-Price; Helle Bielefeldt-Ohmann; Piper Treuting; Brian M Iritani; Weiping Zeng; Andrea Nicks; Mark Tsang; Donna Shows; Phil Morrissey; Joanne L Viney
Journal:  Am J Pathol       Date:  2005-06       Impact factor: 4.307

2.  Circulating IL-1beta levels, polymorphisms of IL-1B, and risk of cervical cancer in Chinese women.

Authors:  Nianfeng Qian; Xiaojun Chen; Suping Han; Fulin Qiang; Guangfu Jin; Xiaoyi Zhou; Jing Dong; Xinru Wang; Hongbing Shen; Zhibin Hu
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-11       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.